These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15816405)

  • 21. Clinical inquiries. How should we monitor men receiving testosterone replacement therapy?
    Alsina M; St Anna L
    J Fam Pract; 2010 Dec; 59(12):711-2. PubMed ID: 21135929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The development of prostate cancer despite late onset androgen deficiency.
    Sengupta S; Duncan HJ; Macgregor RJ; Russell JM
    Int J Urol; 2005 Sep; 12(9):847-8. PubMed ID: 16201985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malignant medication? Testosterone and cancer.
    Pastuszak AW
    BJU Int; 2015 Feb; 115(2):179-80. PubMed ID: 25604717
    [No Abstract]   [Full Text] [Related]  

  • 24. Testosterone replacement therapy and the risk of prostate cancer: a perspective view.
    Barqawi AB; Crawford ED
    Int J Impot Res; 2005; 17(5):462-3. PubMed ID: 15889127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine disrupting compounds and prostate cancer.
    Hess-Wilson JK; Knudsen KE
    Cancer Lett; 2006 Sep; 241(1):1-12. PubMed ID: 16298040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Herbal/hormonal dietary supplement possibly associated with prostate cancer progression.
    Shariat SF; Lamb DJ; Iyengar RG; Roehrborn CG; Slawin KM
    Clin Cancer Res; 2008 Jan; 14(2):607-11. PubMed ID: 18223237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The uses and misuses of testosterone therapy.
    Johns Hopkins Med Lett Health After 50; 2006 Aug; 18(6):3, 7. PubMed ID: 16921650
    [No Abstract]   [Full Text] [Related]  

  • 28. Testosterone replacement therapy and the risk of prostate cancer. Is there a link?
    Barqawi A; Crawford ED
    Int J Impot Res; 2006; 18(4):323-8. PubMed ID: 16281043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastatic prostate cancer after orchiectomy, radiotherapy, and testosterone replacement in a patient with bilateral seminoma.
    Manassero F; Erba P; Mariani G; Mogorovich A; Giannarini G; Selli C
    J Androl; 2007; 28(1):10-2. PubMed ID: 16899814
    [No Abstract]   [Full Text] [Related]  

  • 30. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate Cancer and Testosterone Replacement Therapy--What is the Risk?
    Carson CC; Kirby R
    J Urol; 2015 Dec; 194(6):1527-8. PubMed ID: 26386278
    [No Abstract]   [Full Text] [Related]  

  • 32. Androgen signaling and its interactions with other signaling pathways in prostate cancer.
    Kaarbø M; Klokk TI; Saatcioglu F
    Bioessays; 2007 Dec; 29(12):1227-38. PubMed ID: 18008377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
    Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
    Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
    Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
    Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New concepts regarding the relationship of testosterone and prostate cancer.
    Morgentaler A
    Future Oncol; 2007 Apr; 3(2):123-6. PubMed ID: 17381410
    [No Abstract]   [Full Text] [Related]  

  • 36. Male hormone use soars despite unknown risks.
    Consum Rep; 2004 Feb; 69(2):45. PubMed ID: 15000117
    [No Abstract]   [Full Text] [Related]  

  • 37. Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients.
    Ferreira U; Leitao VA; Denardi F; Matheus WE; Stopiglia RM; Netto NR
    Prostate Cancer Prostatic Dis; 2006; 9(1):39-41. PubMed ID: 16276352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Of fires and frying pans.
    Roth RB; Hess E; Kaminsky AF
    JAMA; 2015 Feb; 313(6):632. PubMed ID: 25668278
    [No Abstract]   [Full Text] [Related]  

  • 39. GREB1 is a novel androgen-regulated gene required for prostate cancer growth.
    Rae JM; Johnson MD; Cordero KE; Scheys JO; Larios JM; Gottardis MM; Pienta KJ; Lippman ME
    Prostate; 2006 Jun; 66(8):886-94. PubMed ID: 16496412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
    Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.